Genetic Research Centre, National Institute for Research in Reproductive Health (ICMR), Jahangir Merwanji Street, Parel, Mumbai, 400 012, India.
Neuromolecular Med. 2013 Mar;15(1):218-25. doi: 10.1007/s12017-012-8212-z. Epub 2012 Dec 15.
Rett syndrome is a severe neurodevelopmental disorder, almost exclusively affecting females and characterized by a wide spectrum of clinical manifestations. Both the classic and atypical forms of Rett syndrome are primarily due to mutations in the methyl-CpG-binding protein 2 (MECP2) gene. Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in patients with atypical Rett syndrome, X-linked infantile spasms sharing common features of generally early-onset seizures and mental retardation. CDKL5 is known as serine/threonine protein kinase 9 (STK9) and is mapped to the Xp22 region. It has a conserved serine/threonine kinase domain within its amino terminus and a large C-terminal region. Disease-causing mutations are distributed in both the amino terminal domain and in the large C-terminal domain. We have screened the CDKL5 gene in 44 patients with atypical Rett syndrome who had tested negative for MECP2 gene mutations and have identified 6 sequence variants, out of which three were novel and three known mutations. Two of these novel mutations p.V966I and p.A1011V were missense and p.H589H a silent mutation. Other known mutations identified were p.V999M, p.Q791P and p.T734A. Sequence homology for all the mutations revealed that the two mutations (p.Q791P and p.T734A) were conserved across species. This indicated the importance of these residues in structure and function of the protein. The damaging effects of these mutations were analysed in silico using PolyPhen-2 online software. The PolyPhen-2 scores of p.Q791P and p.T734A were 0.998 and 0.48, revealing that these mutations could be deleterious and might have potential functional effect. All other mutations had a low score suggesting that they might not alter the activity of CDKL5. We have also analysed the position of the mutations in the CDKL5 protein and found that all the mutations were present in the C-terminal domain of the protein. The C-terminal domain is required for cellular localization through protein-protein interaction; any mutations in this domain might alter this function of the protein. This is the first report from India showing the mutation in CDKL5 gene in Indian cases of Rett syndrome. Our study emphasizes the role of CDKL5 mutation screening in cases of atypical Rett syndrome with congenital seizure variant.
雷特综合征是一种严重的神经发育障碍,几乎只影响女性,其特征是临床表现广泛。经典和非典型雷特综合征主要是由于甲基化-CpG 结合蛋白 2(MECP2)基因突变引起的。在非典型雷特综合征患者中已经发现了 X 连锁周期素依赖性激酶样 5(CDKL5)基因突变,X 连锁婴儿痉挛症具有一般早发性癫痫发作和智力障碍的共同特征。CDKL5 被称为丝氨酸/苏氨酸蛋白激酶 9(STK9),位于 Xp22 区域。它在其氨基末端具有保守的丝氨酸/苏氨酸激酶结构域和一个大的 C 末端区域。致病突变分布在氨基末端结构域和大 C 末端结构域中。我们对 44 例经 MECP2 基因突变检测呈阴性的非典型雷特综合征患者进行了 CDKL5 基因筛查,发现了 6 种序列变异,其中 3 种是新的,3 种是已知的突变。其中两种新的突变 p.V966I 和 p.A1011V 是错义突变,p.H589H 是无义突变。其他已鉴定的已知突变包括 p.V999M、p.Q791P 和 p.T734A。所有突变的序列同源性表明,两个突变(p.Q791P 和 p.T734A)在物种间是保守的。这表明这些残基在蛋白质的结构和功能中很重要。使用在线软件 PolyPhen-2 对这些突变的损伤效应进行了计算机分析。p.Q791P 和 p.T734A 的 PolyPhen-2 评分分别为 0.998 和 0.48,表明这些突变可能是有害的,并且可能具有潜在的功能影响。其他所有突变的评分都较低,表明它们可能不会改变 CDKL5 的活性。我们还分析了 CDKL5 蛋白中突变的位置,发现所有突变都存在于蛋白的 C 末端结构域中。C 末端结构域通过蛋白-蛋白相互作用需要进行细胞定位;该结构域中的任何突变都可能改变该蛋白的功能。这是印度首例报告显示印度雷特综合征病例中 CDKL5 基因突变。我们的研究强调了在具有先天性癫痫发作变异的非典型雷特综合征病例中进行 CDKL5 突变筛查的作用。